Table 6.
Clinical trials for therapies potentially promoting remyelination with trial information and NCT (if available).
| Phase | Count | Trial information | NCT (if available) |
|---|---|---|---|
| 1 | 4 | ||
| Olesoxime | Add-on therapy for Interferon β1 | NCT01808885 | |
| Serum-derived human monoclonal IgM22 | — | NCT01803867 | |
| Thymosin beta4 | — | planned according to RegeneRX | |
| Triiodothyronine | For RRMS, SPMS, and PPMS | NCT02506751, NCT02760056 | |
| 2 | 10 | ||
| Anti-Lingo-1 antibody | Add-on therapy for Interferon β1 | NCT01864148 | |
| Cyclosporin61 | |||
| Electro-acupuncture62 | |||
| Electromagnetic field stimulation63 | |||
| Erythropoietin | PPMS or SPMS | NCT01144117 | |
| Melatonin | RRMS | NCT01279876 | |
| Quetiapine | For RRMS and SPMS | NCT02087631 | |
| Testosteron | For male patients | NCT00405353 | |
| Vitamin E | Combined with Selenium | NCT00010842 | |
| Ebselen | Combined with Vitamin E | NCT00010842 | |
| 3 | 3 | ||
| Laquinimod | For RRMS | NCT01047319 | |
| Minocycline | For clinically isolated syndrome | NCT00666887 | |
| Progesterone | To prevent postpartum relapses | NCT00127075 | |
| 4 | 8 | ||
| Fingolimod | FDA-approved for RRMS | ||
| Fumaric acid ester | FDA-approved for RRMS | ||
| Glatiramer acetate | FDA-approved for RRMS | ||
| Methotrexat | FDA-approved for RRMS | ||
| Methylprednisolone | FDA-approved for RRMS | ||
| Omega-3 poly unsaturated fatty acid (PUFA) diet | For RRMS | NCT01842191 | |
| Simvastatin | Add-on therapy for Interferon β1 (and phase 3 for SPMS) | NCT00492765 | |
| Vitamin D | Add-on therapy for Interferon β1 | NCT01005095 | |
| Total | 25 (30% of the 84 different therapies from our screening) |
Abbreviations: MS, multiple sclerosis; PP, primary progressive; SP, secondary progressive; RR, relapsing remitting.